Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

JTO Clin Res Rep. 2023 Dec 23;5(1):100625. doi: 10.1016/j.jtocrr.2023.100625. eCollection 2024 Jan.

Abstract

We present the first known case of a patient with BRD2::NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2::NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.

Keywords: BRD2::NUTM1 gene fusion; Case report; NUT carcinoma; Non–small cell lung cancer.

Publication types

  • Case Reports